References
  1. Chaudhary S, Ganguly S, Palanichamy JK, Singh A, Pradhan D, Bakhshi R, Chopra A, Bakhshi S. Mitochondrial gene expression signature predicts prognosis of pediatric acute myeloid leukemia patients. Front Oncol. 2023 Feb 9;13:1109518. doi: 10.3389/fonc.2023.1109518. PMID: 36845715
  2. Madney Y, Aboubakr S, Khedr R, Hafez H, Ahmed N, Elsheshtawy K, Elanany M, Salahelden A, Shalaby L, Galal Behairy O. Carbapenem-Resistant Enterobacteriaceae (CRE) among Children with Cancer: Predictors of Mortality and Treatment Outcome. Antibiotics (Basel). 2023 Feb 17;12(2):405. doi: 10.3390/antibiotics12020405. PMID: 36830314
  3. Cerrano M, Bonifacio M, Olivi M, Curti A, Malagola M, Dargenio M, Scattolin AM, Papayannidis C, Forghieri F, Gurrieri C, Tanasi I, Zappasodi P, La Starza R, Fracchiolla NS, Chiusolo P, Giaccone L, Del Principe MI, Giglio F, Defina M, Favre C, Rizzari C, Castella B, Pizzolo G, Ferrara F, Chiaretti S, Foà R. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study. Haematologica. 2022 Apr 1;107(4):996-999. doi: 10.3324/haematol.2021.279851.
  4. Keyhani, A. et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res. 24, 153–159 (2000)
  5. Jeyaraman P, Bhasin A, Dayal N, Pathak S, Naithani R. Daratumumab in dialysis-dependent multiple myeloma. Blood Res. 2020 Mar;55(1):65-67. doi: 10.5045/br.2020.55.1.65.
  6. Farber M, Chen Y, Arnold L, Möllmann M, Boog-Whiteside E, Lin YA, Reinhardt HC, Dührsen U, Hanoun M. Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. Sci Rep. 2021 Nov 11;11(1):22062. doi: 10.1038/s41598-021-01300-8. PMID: 34764342; PMCID: PMC8586007.
  7. Vakrmanová B, Nováková M, Říha P, Žaliová M, Froňková E, Mejstříková E, Starý J, Hrušák O, Šrámková L. CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics. Pediatr Blood Cancer. 2022 Sep;69(9):e29779. doi: 10.1002/pbc.29779. Epub 2022 May 20. PMID: 35592935.
  8. J. Krejcik, T. Casneuf, I.S. Nijhof, B. Verbist, J. Bald, T. Plesner, K. Syed, K. Liu, N.W. van de Donk, B.M. Weiss, T. Ahmadi, H.M. Lokhorst, T. Mutis, A.K. Sasser, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expan- sion, and skews T-cell repertoire in multiple myeloma, Blood 128 (3) (2016) 384–394.
  9. Klimentova M, Shelikhova L, Ilushina M, Kozlovskaya S, Blagov S, Popov A, Kashpor S, Fadeeva M, Olshanskaya J, Glushkova S, Pershin D, Balashov D, Maschan A, Maschan M. Targeted Therapy With Venetoclax and Daratumumab as Part of HSCT Preparative Regimen in Children With Chemorefractory Acute Myeloid Leukemia. Transplant Cell Ther. 2023 Feb;29(2):127.e1-127.e9. doi: 10.1016/j.jtct.2022.11.022.